South Korea · Delayed Price · Currency is KRW Bio Plus Statistics
Total Valuation
Bio Plus has a market cap or net worth of KRW 284.93 billion. The enterprise value is 339.70 billion.
| Market Cap | 284.93B |
| Enterprise Value | 339.70B |
Important Dates
The next estimated earnings date is Friday, August 14, 2026.
| Earnings Date | Aug 14, 2026 |
| Ex-Dividend Date | Dec 29, 2025 |
Share Statistics
Bio Plus has 61.54 million shares outstanding. The number of shares has increased by 19.00% in one year.
| Current Share Class | 61.54M |
| Shares Outstanding | 61.54M |
| Shares Change (YoY) | +19.00% |
| Shares Change (QoQ) | -8.65% |
| Owned by Insiders (%) | 29.20% |
| Owned by Institutions (%) | 4.96% |
| Float | 43.16M |
Valuation Ratios
The trailing PE ratio is 34.70.
| PE Ratio | 34.70 |
| Forward PE | n/a |
| PS Ratio | 3.02 |
| PB Ratio | 1.43 |
| P/TBV Ratio | 1.69 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 16.49 |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 24.27 |
| EV / Sales | 3.60 |
| EV / EBITDA | 19.08 |
| EV / EBIT | 25.44 |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.94, with a Debt / Equity ratio of 0.32.
| Current Ratio | 0.94 |
| Quick Ratio | 0.59 |
| Debt / Equity | 0.32 |
| Debt / EBITDA | 3.55 |
| Debt / FCF | -4.76 |
| Interest Coverage | 43.80 |
Financial Efficiency
Return on equity (ROE) is 10.64% and return on invested capital (ROIC) is 5.91%.
| Return on Equity (ROE) | 10.64% |
| Return on Assets (ROA) | 2.95% |
| Return on Invested Capital (ROIC) | 5.91% |
| Return on Capital Employed (ROCE) | 6.13% |
| Weighted Average Cost of Capital (WACC) | 5.91% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.33 |
| Inventory Turnover | 2.26 |
Taxes
| Income Tax | -2.13B |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -37.85% in the last 52 weeks. The beta is 0.53, so Bio Plus's price volatility has been lower than the market average.
| Beta (5Y) | 0.53 |
| 52-Week Price Change | -37.85% |
| 50-Day Moving Average | 5,432.20 |
| 200-Day Moving Average | 5,648.85 |
| Relative Strength Index (RSI) | 38.15 |
| Average Volume (20 Days) | 582,954 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Bio Plus had revenue of KRW 94.42 billion and earned 14.00 billion in profits. Earnings per share was 133.44.
| Revenue | 94.42B |
| Gross Profit | 63.56B |
| Operating Income | 13.59B |
| Pretax Income | 17.35B |
| Net Income | 14.00B |
| EBITDA | 18.04B |
| EBIT | 13.59B |
| Earnings Per Share (EPS) | 133.44 |
Balance Sheet
The company has 30.74 billion in cash and 64.05 billion in debt, with a net cash position of -33.30 billion or -541.15 per share.
| Cash & Cash Equivalents | 30.74B |
| Total Debt | 64.05B |
| Net Cash | -33.30B |
| Net Cash Per Share | -541.15 |
| Equity (Book Value) | 199.02B |
| Book Value Per Share | 2,893.66 |
| Working Capital | -4.73B |
Cash Flow
In the last 12 months, operating cash flow was 17.28 billion and capital expenditures -30.75 billion, giving a free cash flow of -13.47 billion.
| Operating Cash Flow | 17.28B |
| Capital Expenditures | -30.75B |
| Depreciation & Amortization | 4.45B |
| Net Borrowing | 2.93B |
| Free Cash Flow | -13.47B |
| FCF Per Share | -218.85 |
Margins
Gross margin is 67.31%, with operating and profit margins of 14.39% and 14.82%.
| Gross Margin | 67.31% |
| Operating Margin | 14.39% |
| Pretax Margin | 18.37% |
| Profit Margin | 14.82% |
| EBITDA Margin | 19.11% |
| EBIT Margin | 14.39% |
| FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of 70.00, which amounts to a dividend yield of 1.51%.
| Dividend Per Share | 70.00 |
| Dividend Yield | 1.51% |
| Dividend Growth (YoY) | 40.00% |
| Years of Dividend Growth | 1 |
| Payout Ratio | 20.84% |
| Buyback Yield | -19.00% |
| Shareholder Yield | -17.46% |
| Earnings Yield | 4.91% |
| FCF Yield | -4.73% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on November 23, 2022. It was a forward split with a ratio of 4.
| Last Split Date | Nov 23, 2022 |
| Split Type | Forward |
| Split Ratio | 4 |
Scores
Bio Plus has an Altman Z-Score of 3.19 and a Piotroski F-Score of 6.
| Altman Z-Score | 3.19 |
| Piotroski F-Score | 6 |